Abstract Library

#4581 Clinical efficacy and safety of treatments for pancreatic and extra-pancreatic neuroendocrine tumours following treatment failure or disease progression: A systematic literature review

Introduction: Neuroendocrine tumours (NETs) are a diverse group of rare malignancies with few effective targeted treatments, highlighting a need for novel therapies.

Conference:

Presenting Author:

Authors: Karim E, Srirajaskanthan R, Bensegnor H, Chan K, Drane E,

Keywords: Neuroendocrine tumour, Systematic literature review,

#4576 Economic evidence for pancreatic and extra-pancreatic neuroendocrine tumours following treatment failure or disease progression: A systematic literature review

Introduction: Treatment failure and disease progression (PD) in neuroendocrine tumours (NETs), a rare group of malignancies, are common due to limited targeted treatments.

Conference:

Presenting Author:

Authors: Karim E, Sola-Morales O, Bensegnor H, Chan K, Drane E,

Keywords: Neuroendocrine Tumour, Systematic Literature Review, Economic,

#4427 Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) as second-line and maintenance therapy for neuroendocrine carcinoma with liver metastases: A single-arm, open-label, single-centre phase II clinical study (SuHaNec)

Introduction: Neuroendocrine carcinoma (NEC) is rare and highly aggressive, and liver metastasis leads to worse outcomes for patients (pts) with limited treatment options and poor prognosis. Surufatinib (SUR) exhibited promising antitumour activity in neuroendocrine neoplasms.

Conference:

Presenting Author:

Authors: Wang Y, Wang J, Yang D, Yao W, Zhang N,

Keywords: neuroendocrine carcinoma, surufatinib, hepatic artery infusion chemotherapy, later-line treatment,

#4293 Efficacy of FOLFOX chemotherapy combined with anti-angiogenic targeted drugs (bevacizumab/surufatinib) in neuroendocrine tumours after progression following multiple lines of therapy: A retrospective study

Introduction: The FOLFOX regimen (combining 5-fluorouracil, leucovorin, and oxaliplatin) has been widely used for treating various cancers, including NETs. However, the effectiveness of combining FOLFOX with antiangiogenic agents in NETs after progression on multiple therapies remains unclear.

Conference:

Presenting Author: Liang Y

Authors: Liang Y, Jia X, Sun Z, Chen J,

Keywords: FOLFOX, chemotherapy, antiangiogenic agents, G3,

#3964 Genomic profiling in the randomised controlled phase III COMPOSE trial of Lu-177 edotreotide for well-differentiated aggressive grade 2/3 gastroenteropancreatic-neuroendocrine tumors

Introduction: Targeted radiopharmaceutical therapy (RPT) has demonstrated potential in treatment of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). However, RPT exhibits variable outcomes and lacks tools to predict individual efficacy. To address the latter, a genomic profiling analysis was included in the randomised, controlled, open-label, phase III COMPOSE trial of Lu-177 edotreotide vs. best standard of care (CAPTEM, FOLFOX or everolimus) in patients with well differentiated, aggressive, G2/G3 somatostatin receptor-positive GEP-NETs.

Conference:

Presenting Author:

Authors: Srirajaskanthan R, Capdevila J, Halfdanarson T, Halperin D, Herrmann K,

Keywords: radiopharmaceutical therapy, genomic, Lu-177 edotreotide, gastroenteropancreatic, tumor, neuroendocrine,